DCH Auriga - Healthcare


DCH Auriga - Healthcare
Concise Prescribing Info
Monotherapy for the treatment of adults w/ unresectable or metastatic GI stromal tumours harbouring the platelet-derived growth factor receptor α D842V mutation.
Dosage/Direction for Use
Should be taken on an empty stomach: Avoid grapefruit or grapefruit juice.
Special Precautions
Associated w/ an increased incidence of haemorrhagic events eg, GI haemorrhage, hepatic, tumour & intracranial haemorrhages. Permanently discontinue if intracranial haemorrhage is observed during treatment. Cognitive effects eg, memory impairment, cognitive disorder, confusional state, encephalopathy; fluid retention; QT interval prolongation; diarrhoea, nausea, vomiting; anaemia, neutropenia, thrombocytopenia; elevations in bilirubin & liver transaminases. Caution in patients w/ known QT interval prolongation or at risk of QT interval prolongation. Perform CBC on a regular basis during treatment. Regularly monitor liver function (transaminases, bilirubin). Avoid or minimise exposure to direct sunlight due to risk of phototoxicity. Avoid co-administration w/ strong or moderate CYP3A inhibitors or inducers. May influence the ability to drive & use machines. Not recommended in patients w/ severe hepatic impairment or severe renal impairment or end-stage renal disease. May cause foetal harm. Women of childbearing potential should use effective contraception during treatment & for 1 mth after the last dose. Not recommended during pregnancy & in women of childbearing potential not using contraception. Discontinue breastfeeding during treatment & for 2 wk following the final dose.
Adverse Reactions
Anaemia, decreased WBC, decreased neutrophil count; decreased appetite; memory impairment, cognitive disorder, dizziness, taste effect; increased lacrimation; abdominal pain, vomiting, diarrhoea, nausea, dryness, GERD; hyperbilirubinaemia; hair colour changes, rash; oedema, fatigue; increased transaminases.
Drug Interactions
Increased plasma conc w/ strong or moderate CYP3A inhibitors (eg, antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides eg, erythromycin, clarithromycin & telithromycin; active substances to treat HIV/AIDS eg, cobicistat, indinavir, lopinavir, nelfinavir, ritonavir & saquinavir; as well as conivaptan & boceprevir) including grapefruit or grapefruit juice. Decreased plasma conc w/ strong or moderate CYP3A4 inducers [eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarb, fosphenytoin, primidone, bosentan, efavirenz, etravirine, modafinil, dabrafenib, nafcillin or Hypericum perforatum (St. John's wort)]. May have potential to increase or decrease plasma conc of CYP3A substrates. Has potential to alter conc of co-administered substrates of P-gp, BCRP, MATE1, MATE2-K, & BSEP.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EX18 - avapritinib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.
Ayvakit FC tab 100 mg
Ayvakit FC tab 300 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in